The European Medicines Agency June 17 issued updated guidance on postmarketing authorization measures, spelling out five types of postapproval studies the agency may specify during review of a marketing authorization application. The most serious category — a specific obligation — is reserved for marketing authorizations that are granted under exceptional circumstances or with special conditions.
International Pharmaceutical Regulatory Monitor